Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.

NCT02459262 | Completed Phase 1 Results DMC

• 1 other identifier: 2014-004542-10
• Study Type: interventional
• Target: 240
• Locations: 1 country
• Sites: 1

Brief Summary

Part A: The primary objective is to evaluate the safety and tolerability of a potential vaccine against Group B streptococcus. Part B: To evaluate the long term safety profile of the GBS-NN vaccine up to one year following the first dose.

Conditions

Infection by Streptococcus Group B

Outcome Measures

Primary Outcomes (2)

• Part A Number of Participants With Treatment Emergent Adverse Events

  Number of Participants with Treatment Emergent Adverse Events

  12 weeks (to Day 85)

• Part B Number of Participants With Treatment Emergent Adverse Events

  Number of Participants with Treatment Emergent Adverse Events

  12 weeks (to Day 85)

Secondary Outcomes (4)

• Part A Antibody Concentration

  12 weeks (Day 85)

• Part B Antibody Concentration

  12 weeks (Day 85)

• Part B Antibody Concentration

  1 year (Day 365)

• Part B Number of Participants With Treatment Emergent Adverse Events

  Day 85 to Day 365

Study Arms (2)

GBS-NN Vaccine

ACTIVE COMPARATOR

GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.

Biological: GBS-NN vaccine

Sterile dilution buffer with Alhydrogel

PLACEBO COMPARATOR

The placebo will contain either Alhydrogel® or buffer alone.

Biological: GBS-NN vaccine

Interventions

GBS-NN vaccine BIOLOGICAL

Three dose levels will be administered, with and without Alhydrogel®

GBS-NN Vaccine; Sterile dilution buffer with Alhydrogel

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult female volunteers (as determined by medical history, physical examination, laboratory test values, vital signs and electrocardiograms \[ECGs\] at screening) aged 18 - 40 years.
• Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2.
• Volunteers weight ≥ 50kg and ≤100kg at screening.
• Able to voluntarily provide written informed consent to participate in the study.
• Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol.
• Volunteers must be pre-menopausal. Volunteers who have had a hysterectomy will have pre-menopausal status confirmed by a FSH and oestradiol test.
• Females of childbearing potential must have a negative pregnancy test at screening (β HCG) and prior to each dose and must be willing to use an adequate and highly effective method of contraception until at least Day 85 of the study. A highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, IUDs (Intrauterine Device), condoms, occlusive caps (cervical/vault caps) with spermicidal foam/gel/ film/cream/suppository. True sexual abstinence is acceptable when this is in line with the preferred and usual lifestyle of the volunteer (periodic abstinence e.g. calendar, ovulation, symptothermal, post-ovulation methods, declaration of abstinence for the duration of the trial, and withdrawal are not acceptable methods of contraception)
• In Part A: Volunteers must be non-smokers for at least 3 months prior to first studyvaccine administration. In Part B: Volunteers may be light smokers i.e. up to a maximum of 5 cigarettes per day or nicotine equivalent.
• Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).
• The volunteer's primary care physician has confirmed within the last 12 months that there is nothing in their medical history that would preclude their enrolment into a clinical trial.

You may not qualify if:

• Volunteers with history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, psychiatric, autoimmune disease or current infection.
• Pregnant or lactating females.
• Laboratory values at screening which are deemed to be clinically significant, unless agreed in advance by the Sponsor's Responsible Medic and Principal Investigator.
• Current or history of drug or alcohol abuse, or a positive alcohol breath test prior to first dosing.
• Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
• Participation in a clinical drug study during the 90 days preceding the initial dose in this study.
• Any significant illness during the 4 weeks preceding check-in for this study (Day 1).
• Volunteers with a history of severe allergic reactions after previous vaccination.
• Volunteers who have received any vaccine within 30 days of screening, or who are planning to receive a vaccine up to Day 85 of the study.
• Volunteers receiving immunosuppressive therapy (e.g. systemic steroids, cancer therapies, methotrexate, azathioprine) in the 6 months prior to screening, antibiotics within 10 days of receiving the first dose or taking any short-term medications including over-the-counter preparations, vitamins, herbal and/or mineral supplements within 7 days of the first dose. Chronic medications such as antihypertensives, bronchodilators, oral contraceptives or statins that do not affect the immune system, will be permitted and allowed to continue during the study at the discretion of the Investigator. Paracetamol will be permitted for the treatment of headache or other symptoms.
• Volunteers with tattoos at the proposed site of vaccine administration.
• Donation of blood or blood products within 90 days prior to vaccine administration.
• Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.

Sponsors & Collaborators

• Minervax ApS: lead

Study Sites (1)

Biokinetic Europ Ltd

Belfast, BT2 7BA, United Kingdom

Location

Related Publications (2)

• Pawlowski A, Lannergard J, Gonzalez-Miro M, Cao D, Larsson S, Persson JJ, Kitson G, Darsley M, Rom AL, Hedegaard M, Fischer PB, Johansson-Lindbom B. A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains. Cell Rep Med. 2022 Feb 15;3(2):100511. doi: 10.1016/j.xcrm.2022.100511. eCollection 2022 Feb 15.

  PMID: 35243418 DERIVED

• Fischer P, Pawlowski A, Cao D, Bell D, Kitson G, Darsley M, Johansson-Lindbom B. Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women. Vaccine. 2021 Jul 22;39(32):4489-4499. doi: 10.1016/j.vaccine.2021.06.046. Epub 2021 Jun 30.

  PMID: 34215454 DERIVED

Results Point of Contact

• Title: Per Fisher DPhil
• Organization: MinervaX ApS

pbf@minervax.com

+45 20 25 20 38

Study Officials

• Per Fisher, PM/CEO

  MinervaX ApS, Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 22, 2015
• First Posted: June 2, 2015
• Study Start: May 1, 2015
• Primary Completion: April 12, 2017
• Study Completion: April 21, 2017
• Last Updated: January 14, 2021
• Results First Posted: January 14, 2021

Record last verified: 2020-11

Locations

GB (1)